15:32 , May 25, 2018 |  BC Week In Review  |  Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
23:26 , May 18, 2018 |  BC Extra  |  Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
21:53 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Abeona reports top-line Phase I/II data for ABO-102 in mucopolysaccharidosis IIIA

In October, Abeona Therapeutics Inc. (NASDAQ:ABEO) reported top-line data from the first cohort of 3 patients with mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo type A syndrome) in a Phase I/II trial showing that IV ABO-102 (AAV-SGSH)...
00:34 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Abeona raises $92M in follow-on

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) raised $92 million through the sale of 5.8 million shares at $16 in a follow-on underwritten by Jefferies, RBC Capital Markets, Cantor Fitzgerald, FBR Capital Markets, H.C. Wainwright,...
21:42 , Oct 17, 2017 |  BC Extra  |  Financial News

Abeona raises $80M in follow-on

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) raised $80 million through the sale of 5 million shares at $16 in a follow-on underwritten by Jefferies, RBC Capital Markets, Cantor Fitzgerald, FBR Capital Markets, H.C. Wainwright,...
11:38 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

ABO-102: Interim Ph I/II data

Interim data from 3 patients with MPS IIIA in an open-label, U.S. Phase I/II trial showed that a single IV injection of 5x10 12 vg/kg ABO-102 was well tolerated with no treatment-related serious adverse events...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

ABO-102: Phase I/II ongoing

A DSMB recommended continuation to the high-dose cohort of an open-label, U.S. Phase I/II trial evaluating single doses of 2 dose levels of IV ABO-102 based on a review of safety data from 3 patients...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

ABO-102: Phase I/II ongoing

Abeona enrolled the second patient in an open-label, U.S. Phase I/II trial evaluating single doses of 2 dose levels of IV ABO-102 based on a DSMB review of safety data from the first patient enrolled....
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

ABO-102: Phase I/II started

Abeona began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate single doses of 2 dose levels of IV ABO-102 in about 9 patients. Abeona Therapeutics Inc. (NASDAQ:ABEO), Dallas, Texas   Product: ABO-102 (formerly ABX-A...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Abeona, PlasmaTech Biopharmaceuticals deal

PlasmaTech acquired Abeona for 4 million PlasmaTech shares, or about $31.9 million based on PlasmaTech’s close of $7.98 on May 15, the last trading day before the deal closed. In mid-2015, the company plans to...